🔎 Trials Near Me

Home › Leukemia › NCT06487247

HEME Home Transfusion Program

Recruiting

Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria for Patient Participants:

* Diagnosis of a relapsed/refractory hematologic malignancy
* Age ≥ 18 years
* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
* Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction
* Patient resides within catchment served by Care Dimensions Hospice
* Physician-estimated prognosis of six months or less

Inclusion Criteria for Caregivers:

* Identified informal caregiver of enrolled patient with hematologic malignancy
* Age ≥ 18 years

Exclusion Criteria for Patient Participants:

* Age \< 18 years
* Already enrolled in hospice
* Resides in nursing home or assisted living facility
* History of previous serious adverse transfusion reaction

Exclusion Criteria for Caregivers:

-Age \< 18 years

About the study

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.

What is being tested

Sponsor: Dana-Farber Cancer Institute · Participants: 700 · Started: Sep 10, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06487247

Locations in the U.S.

MassachusettsBrigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.